fda okay burroughs wellcome azt aid treatment food drug administration approve burroughs wellcome azt treatment help aid patient include advancedaids relate complex drug approve treatment aid azt azidothymidine market retrovir company arm britain wellcome plc limit supply fda drug restrict initially patient aid aidsrelated complex severely depress immunity history pnumocystis carinii pneumonia approval mark step mean final victory ongoing aid dr robert windom assistant secretary health public health service note available clinical data sufficient approve retrovir indication aid associate condition nevertheless windom action mean significant medical relief available thousand afflict disease retrovir cure demonstrate ability improve shortterm survival aid patient recently diagnose pcp pneumomystis carinii pneumonia patient advance arc aidsrelated complex windom advance aid relate complex condition frequently precede develop short time fullscale acquire immune deficiency syndrome march aid report nationwide death public health agency advance arc patient symptom include weight loss persistent fever diarrhea severe infection oral thrush herpes infection federal agency aid patient expect qualify retrovir treatment serious opportunistic infection associate aid advance aid relate complex estimate time american suffer advance arc aid burroughs wellcome research triangle park schedule press conference monday york discus patient quality treatment company treatment drug cost dollar dollar burroughs adequate supply drug seriously patient supply minimum patient probably retrovir approval expect panel expert medical adviser fda recommend january drug license sale gap understand drug effectiveness panel drug prolong life aid patient cause severe effect anemia blood due extraordinary situation surround aid fatal disease reach health official epidemic proportion windom fda move near record timefour monthsto approve drug azt derive herring sperm create jerome horwitz michigan cancer foundation anticancer agent meanwhile london dealer wellcome share rise response night close pharmaceutical analyst mark clark barclays zoete wedd drug share market expect severe effect cure effect bad unlikely support treatment host drug market soon week drug approve market uk 
